TREMBLAY ET AL.
BRIEF DEFINITIVE REPORT were obtained from three HIV-1-infected individuals. Two of these patients were asymptomatic and one fulfilled the criteria for AIDS ofthe Centers for Disease Control (12) . Additional sera from healthy sero-negative donors were used as controls . Sera were heat inactivated (HI) for 30 min at 56°C before use. Lyophilized human complement-containing serum from Sigma Chemical Co. (St . Louis, MO) was used as a source of human complement and was reconstituted immediately before use. Viruses. The HIVIII R strain of HIV-1 was harvested from culture fluids of the chronically infected H-9 T lymphoid cell line, kindly supplied by Dr. R. C. Gallo (National Institutes of Health, Bethesda, MD) (13) . A clinical variant of HIV1, recently isolated in our laboratory by a coculture assay (14) , was also included in the study. Titers of these HIV-1 preparations were determined by plaque assay using MT-4 cells (HTLV I-carrying cells) as targets (15) .
Immuno,fluorescence and Progeny Virus Production . The presence of HIV-1 antigens was detected by an indirect immunofluorescence assay. Toward this end, mouse mAbs specific for the viral core protein p24 (kindly supplied by Dr. R. C. Gallo) were used in conjunction with a FITC-conjugated goat anti-mouse Ig (Cappel Laboratories, Cochranville, PA) . Infectious titers (TCID50) of progeny virus production in culture supernatant fluids were calculated using the Karber formula, on the basis of viral cytopathicity for MT-4 cells .
Flow Cytometry. Mouse mAbs used in these studies were anti-Leu-3a (anti-CD4) (Becton Dickinson Immunocytometry Systems, Mountain View, CA) and OKB7 (anti-CR2) (Ortho Diagnostics Systems Inc., Westwood, MA) . EBVpositive B cells were first incubated with the appropriate mAb, washed, and incubated with FITC-conjugated goat anti-mouse Ig. The fluorescence data of 10,000 cells were analyzed using a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems). Nonspecific stainingwas determined using nonbinding isotype-matched mAbs.
Complement-mediated ADE of HIV-1 Infection . 200,ul of culture fluid containing HIV-1 (105 TCID5o for HIVIIIR, and 10°TCID5o for the clinical isolate) was mixed with an equal volume of HI HIV-1 antibody-positive serum, supplemented with 1 :20 human complement-containing serum, and incubated for 1 h at 37°C. Then, 5 x 105 EBVcarrying B cells were added to each sample and incubated for 2 h at 37°C. The cells were washed twice and resuspended in 500 11 offresh medium before seeding . Samples were harvested periodically and assayed for viral infection . Controls were performed using sera from HIV-1 antibody-negative individuals .
Results and Discussion
The role of complement-mediated antibody-dependent enhancement (CM-ADE) ofHIV infection was studied in two independently derived EBVcarrying B cell lines. These two cell lines (A and B) expressed variable levels of both CR2 (Fig. 1 , A and C) and CD4 ( Fig. 1 , B and D), as shown by flow cytometry histograms . Although these two cell lines also expressed Fc receptors, we could not detect any ADE ofHIV-1 infectivity using sera from each of three seropositive individuals (Fig. 2) .
The two B cell lines were infected with HIVIIIB in the presence of the abovementioned HIV-1-positive sera and a constant amount ofhuman complement (1 :20). The results of Fig . 2 A indicate that a significant increase (2-5-fold) in the number of cells expressing HIV-1 p24 antigen was observed in cell line A, after 8 d of exposure to the virus. Cell line B, which expressed low levels of CR2 and CD4, was almost nonsusceptible to HIV-1 infection (Fig. 2 B) . However, when these cells were incubated with HIV III$, together with the above-mentioned sera and complement, a 5-10-fold increase in the percentage of cells that expressed p24 was observed .
To confirm that this phenomenon was not restricted to HIV-114, the same experiments were performed on cell line A with a clinical isolate of HIV-1 . As shown in Fig. 2 C, a similar enhancement effect was observed in the CM-ADE assay. We also investigated whether the CM-ADE of HIV-1 infection would result in increased progeny virus production . Table I shows that the yields ofinfectious virus in culture supernatants were increased by 3-10-fold when cells were infected in the presence of any of three samples of HIV-1-positive sera and human complement. It has been reported that HIV-1-infected EBVpositive B cells can be isolated from the PBMC ofpatients with AIDS-related complex (ARC) and AIDS (16) . Our results support the notion that EBVtransformed B cells, which are noteworthy for their high expression of CR2 and which can also express CD4, may participate in the pathogenesis ofdisease by releasing more infectious viral particles after HIV-1 infection through the CM-ADE mechanism.
Experiments were performed to determine what the effect of complement depletion would be on the observed CM-ADE of HIV-1 infection. Fig. 2 D indicates that cobra venom factor, which is known to cause the inactivation of C3, inhibited the CM-ADE of HIV-1 infection when included in the assay.
We next carried out a series of experiments to identify the molecules involved in the CM-ADE of HIV-1 infection. The involvement of CD4 in the CM-ADE mechanism was clearly demonstrated by the observation that anti-Leu-3a, a mAb specific for the gp120 binding site ofCD4, totally abrogated HIV-1 infection in the presence of HIV-1-positive sera and complement (Fig. 3 A) . This inhibition occurred at concentrations as low as 25 ng/ml, confirming that CD4 is the primary binding site for HIV1 . Fig. 3 B shows that mAb OKB7, which is specific for the CR2, inhibited the increase in p24-positive cells in a dose-dependent fashion. Complete inhibition of the CM-ADE was observed when 10 /kg/ml of OKB7 was used. Control experiments were performed using D1-12, a mAb specific to MHC class II molecules. This mAb did not inhibit HIV-1 infection.
These results indicate that CD4 and CR2 synergize for the entry of HIVI into EBVtransformed B cells. This'synergy might be relatively important in cells that express low levels of CD4 and/or where the fusion-mediated entry of HIV-1 is inefficient (e.g., cell line B) . In our model, the CR2 structure would permit HIV-1 infection through viral endocytosis after initial binding to CD4. It is relevant that CR2 has previously been reported to mediate the internalization of EBV via an endocytic pathway (17) . The phenomenon of CM-ADE of HIV-1 infection observed in EBVcarrying B cells thus involves each the CD4 receptor, the CR2, and complement . This enhancement of HIV-1 infection was detected using sera from each of two asymptomatic individuals and one patient with AIDS . Our results suggest that HIV-1 may be able to more efficiently infect EBVcarrying B cells in vivo through a CD4-CR2 receptor complex. This may allow for circumvention ofthe effects of neutralizing antibodies.
It is further relevant that, in contrast to normal B cells, most EBVtransformed B cell lines express cell surface CD4 to some degree (18) . Indeed, the ability ofHIV-1 to infect such cells can be blocked by anti-CD4 antibodies, regardless of the extent ofcell surface CD4 representation . This issue may have important clinical relevance, given that the numbers of EBVtransformed B cells are elevated in patients with AIDS and, accordingly, could represent an important target for HIV-1 in such individuals (18) . Moreover, EBVcarrying B cells are relatively resistant to the cytopathic effects of HIV1, in comparison with T lymphocytes (18) .
Summary
Although the CD4 glycoprotein is the primary receptor for HIV-1, recent reports have suggested that other molecules might be involved in the enhancement ofHIV-1 infection. We investigated the possible role ofthe complement receptor 2 in enhancement of HIV-1 infection in CD4+ EBVcontaining B cells by infecting such cells in the presence of sera from HIV sero-positive donors, with or without added human complement . A marked increase in production of viral p24 and infectious progeny virus was observed only when infection had been carried out in the presence ofhuman complement . The addition of mAb to the human complement receptor 2 completely inhibited this enhancement. This mechanism was CD4 dependent, suggesting a cooperative effect between these two ligands in the potentiation of viral entry.
